Scinai Immunotherapeutics Ltd.
SCNIRating Trend
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 24, 2026 | $-0.74 | — | $467.9K | — |
| Jun 10, 2026 | $9.40 | — | $487.7K | — |
| Apr 1, 2026 | $-2720.00 | — | $269.0K | — |
| Nov 2, 2025 | $-35.70 | — | $277.3K | — |
| Sep 2, 2025 | $-1.20 | — | $386.5K | — |
| May 7, 2025 | $-10.40 | — | $386.5K | — |
| Nov 22, 2024 | $8.40 | — | $168.0K | — |
| Aug 15, 2024 | $-3.57 | — | $284.0K | — |
News
October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today reported financial results for the nine months ended September 30, 2026, and provided a business updat…
Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and delivered JERUSALEM, Oct. 20, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) today issued the following letter to shareholders from Chief Executive Officer Amir Reichman.
JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placement of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares…
JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares ("ADSs") (or …
Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027 Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late 2027 through the first half of 2028, excluding additional scale-up, qualification and initial manufacturing …
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd.
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.